| 1 |
Pan Y, Xia H, He Y, Zeng S, Shen Z, Huang W. The progress of molecules and strategies for the treatment of HBV infection. Front Cell Infect Microbiol 2023;13. [DOI: 10.3389/fcimb.2023.1128807] [Reference Citation Analysis]
|
| 2 |
Jiang B, Dai Q, Liu Y, Yu G, Mi Y. Levels of HBV RNA in chronic HBV infected patients during first-line nucleos(t)ide analogues therapy. Infect Agent Cancer 2022;17:61. [PMID: 36476371 DOI: 10.1186/s13027-022-00473-9] [Reference Citation Analysis]
|
| 3 |
Pol S. Withdrawal of Nucleos(t)ide Analogues in the Treatment of Chronic Hepatitis B: A Cornelian Choice. Gastroenterology 2022;162:698-9. [PMID: 34914942 DOI: 10.1053/j.gastro.2021.12.240] [Reference Citation Analysis]
|
| 4 |
Zhang Q, Cai DC, Hu P, Ren H. Low-level viremia in nucleoside analog-treated chronic hepatitis B patients. Chin Med J (Engl) 2021;134:2810-7. [PMID: 34759219 DOI: 10.1097/CM9.0000000000001793] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 5 |
Capozza P, Decaro N, Beikpour F, Buonavoglia C, Martella V. Emerging Hepatotropic Viruses in Cats: A Brief Review. Viruses 2021;13:1162. [PMID: 34204394 DOI: 10.3390/v13061162] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 6 |
Shen C, Feng X, Mao T, Yang D, Zou J, Zao X, Deng Q, Chen X, Lu F. Yin-Yang 1 and HBx protein activate HBV transcription by mediating the spatial interaction of cccDNA minichromosome with cellular chromosome 19p13.11. Emerg Microbes Infect. 2020;9:2455-2464. [PMID: 33084547 DOI: 10.1080/22221751.2020.1840311] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 7 |
Tan M, Ren F, Yang X. Anti-HBV therapeutic potential of small molecule 3,5,6,7,3',4'-Hexamethoxyflavone in vitro and in vivo. Virology 2021;560:66-75. [PMID: 34051476 DOI: 10.1016/j.virol.2021.05.007] [Reference Citation Analysis]
|
| 8 |
Lowjaga KAAT, Kirstgen M, Müller SF, Goldmann N, Lehmann F, Glebe D, Geyer J. Long-term trans-inhibition of the hepatitis B and D virus receptor NTCP by taurolithocholic acid. Am J Physiol Gastrointest Liver Physiol 2021;320:G66-80. [PMID: 33174454 DOI: 10.1152/ajpgi.00263.2020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 9 |
Shi Y, Du L, Lv D, Li Y, Zhang Z, Huang X, Tang H. Emerging role and therapeutic application of exosome in hepatitis virus infection and associated diseases. J Gastroenterol 2021;56:336-49. [PMID: 33665710 DOI: 10.1007/s00535-021-01765-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 10 |
Sun H, Chang L, Yan Y, Wang L. Hepatitis B virus pre-S region: Clinical implications and applications. Rev Med Virol 2020. [PMID: 33314434 DOI: 10.1002/rmv.2201] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 11 |
Rybicka M, Bielawski KP. Recent Advances in Understanding, Diagnosing, and Treating Hepatitis B Virus Infection. Microorganisms. 2020;8. [PMID: 32942584 DOI: 10.3390/microorganisms8091416] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 12 |
Li X, Liu H, Cheng W, Wang J, Zhang H, Lu F, Chen X, Lin W. Junceellolide B, a novel inhibitor of Hepatitis B virus. Bioorg Med Chem 2020;28:115603. [PMID: 32690259 DOI: 10.1016/j.bmc.2020.115603] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
